US stocks wavered on Friday but were on track for weekly losses as Wall Street digested a cooler-than-expected inflation reading for a steer on the path of interest rates. The Dow Jones Industrial Average (^DJI) and the tech-heavy Nasdaq Composite (^IXIC) drifted below the flatline. Meanwhile, the S&P 500 (^GSPC) flipped between small gains and losses, coming off a day of intense selling pressure on tech stocks. Inflation cooled more than expected in January, data released Friday by the Bureau of Labor ...

Market Overview - US stocks experienced a rise on Friday, with the S&P 500 gaining approximately 0.6%, while the Dow Jones Industrial Average and Nasdaq Composite increased by roughly 0.4% and 0.5% respectively, despite being on track for weekly losses [1] Inflation Data - The Consumer Price Index indicated that consumer prices rose by 0.2% in January compared to the previous month and increased by 2.4% year-over-year, reflecting a cooler-than-expected inflation reading [2] Federal Reserve Expectations - The inflation report is expected to influence Federal Reserve policy, with traders increasing bets on a potential quarter-point interest rate cut in June, while most anticipate two cuts by the end of 2026 [3] Sector Performance - The market saw significant selling pressure due to concerns about AI disruption affecting traditional sectors like real estate, logistics, and transportation, leading to sharp weekly losses for the Dow, S&P 500, and Nasdaq [4] Earnings Reports - Applied Materials (AMAT) stock surged by up to 10% following a positive outlook driven by strong AI demand, while Pinterest (PINS) shares fell by as much as 20% due to revenue shortfalls and concerns over AI risks [5] - Rivian (RIVN) shares increased by over 25% after beating fourth-quarter earnings expectations, with plans for its R2 midsize model to be delivered before summer, and Moderna (MRNA) shares rose by 10% after exceeding quarterly revenue estimates due to strong sales of its Covid vaccine [6]

Question-and-Answer SessionAnd maybe we can just kick off if you can give a brief overview of Ascentage and where you are today, core focus of the company, where you've got the footprint and what you see as really the key pillars of the strategy for the company.Veet MisraChief Financial Officer Yes. Thank you for the question. So Ascentage is a public company, dual listed on both the NASDAQ and Hong Kong Stock Exchange. We're a global company, close to 800 employees at this point. We're a commercial stage i ...

Market Overview - Overseas stock markets showed mixed results, with the Euro Stoxx 50 down by -0.40%, China's Shanghai Composite up by +0.05%, and Japan's Nikkei Stock 225 down by -0.02% [1] - The S&P 500 Index closed down -1.57%, the Dow Jones Industrial Average down -1.34%, and the Nasdaq 100 Index down -2.04% [6] Earnings Reports - Over two-thirds of S&P 500 companies have reported earnings, with 76% beating expectations. S&P earnings growth is projected to increase by +8.4% in Q4, marking the tenth consecutive quarter of year-over-year growth [2] - Excluding the Magnificent Seven technology stocks, Q4 earnings are expected to rise by +4.6% [2] - Cisco Systems fell more than -12% after indicating that higher memory-chip prices would impact profitability [5][14] - ICON Plc closed down more than -39% due to an internal investigation into accounting practices, suggesting revenue may have been overstated by less than 2% [13] - Tyler Technologies reported Q4 total revenue of $575.2 million, below the consensus of $590.8 million, leading to a decline of more than -15% [14] Sector Performance - The Magnificent Seven technology stocks experienced a sell-off, with Apple down more than -5% and Amazon, Meta, and Tesla down more than -2% [10] - Trucking and logistics companies faced significant declines amid concerns over AI disruption, with Landstar Systems down more than -15% and CH Robinson down more than -14% [11] - Cryptocurrency-exposed stocks fell after Bitcoin declined by more than -3%, with Coinbase down more than -7% [12] Economic Indicators - US January existing home sales fell -8.4% month-over-month to a 16-month low of 3.91 million, below expectations of 4.5 million [3] - Lower bond yields supported stocks, with the 10-year T-note yield falling to a 2.25-month low of 4.10% [4][7] - UK Q4 GDP rose by +0.1% quarter-over-quarter and +1.0% year-over-year, which was weaker than expected [8]

Market Overview - U.S. stocks experienced a significant decline on February 12th, 2026, with the Dow Jones Industrial Average falling 1.03% to 49,605.19, the S&P 500 down 1.13% to 6,862.95, and the Nasdaq Composite dropping 1.61% to 22,695.23, driven by concerns over artificial intelligence's impact on corporate profits and anticipation of inflation data [1][2] Corporate Movers - Cisco Systems (CSCO) saw its stock drop approximately 10% despite exceeding earnings expectations, primarily due to disappointing forward guidance that raised growth concerns [3] - AppLovin (APP) experienced a dramatic sell-off, with shares tumbling around 18.3% despite reporting stronger-than-expected profits, reflecting market anxieties about AI disrupting software business models [4] - Micron Technology (MU) had a positive stock movement following optimistic comments from its CFO regarding next-generation HBM4 memory production, a key component for AI infrastructure [5] - McDonald's (MCD) shares rose after reporting stronger-than-anticipated profits, while Walmart (WMT) also performed well, contributing positively to the S&P 500 [6] - Tenet Healthcare Corporation (THC) surged after a strong earnings report, and T-Mobile US, Inc. (TMUS) rose after beating earnings estimates, while Shopify Inc. (SHOP) and Moderna, Inc. (MRNA) faced declines due to missing earnings expectations and FDA decisions, respectively [7] Sector Movements - In the energy sector, coal stocks like Peabody Energy (BTU) and Hallador Energy (HNRG) gained momentum following executive orders from the Trump administration aimed at supporting the coal industry [8] Economic Outlook - The upcoming U.S. Consumer Price Index (CPI) release is expected to significantly influence market direction, with investors closely monitoring it for signs of inflationary pressures, which will impact the Federal Reserve's interest rate decisions [9]

Core Insights - The biotech sector is attracting savvy investors due to the potential for significant growth, particularly with advancements in artificial intelligence enhancing medical breakthroughs in various therapeutic areas [1] Company Overview - Kura Oncology has transitioned from a clinical-stage to a commercial-stage biotech company following FDA approval of its cancer drug, KOMZIFTI [2][6] - The company is valued at $682.2 billion and focuses on developing targeted small-molecule drugs for cancer treatment [6] Stock Performance and Projections - Kura's stock is down 24% year-to-date, but analysts project a potential surge of up to 850% by 2026 [2] - The average target price for Kura stock is set at $32.45, indicating a potential upside of over 311% from current levels, with a street-high estimate of $76 suggesting an upside of 864% in the next 12 months [4] Market Context - Historical examples in the biotech sector, such as Moderna's 1,227% stock surge due to its COVID-19 vaccine, illustrate the potential for substantial returns when a drug successfully hits the market [5] - Kura's lead drug, KOMZIFTI, addresses a significant unmet need for patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific NPM1 mutation [7]

Aclaris Therapeutics Conference Call Summary Company Overview - **Company**: Aclaris Therapeutics (NasdaqGS: ACRS) - **Focus**: Clinical stage biopharmaceutical company specializing in large molecule and small molecule therapeutics [4][5] Key Developments and Programs Large Molecule Therapeutics - **TSLP Monoclonal Antibody**: Currently in a 90-patient study for moderate to severe atopic dermatitis (AD), with results expected in late 2026 [4] - **Bispecific Antibody**: Built off the TSLP monoclonal antibody with an IL-4R construct, showing highly positive pharmacokinetic/pharmacodynamic (PK/PD) data [4][5] - **Phase 1b Studies**: Ongoing studies for severe AD and moderate asthma, with readouts also expected in late 2026 [5] Small Molecule Therapeutics - **ITK Franchise**: Lead molecule 2138 is an ITK JAK3 inhibitor, ready for Phase IIb trials. The company is selecting a lead indication for this asset [5][6] - **Next Generation ITK**: Development of super selective ITK inhibitors, with IND enabling discussions ongoing [6] Clinical Data and Efficacy - **Bosakitug (TSLP-targeted monoclonal)**: Demonstrated a 94% EASI-75 response and an 88% IGA 0/1 in previous studies, indicating strong efficacy [9][10] - **Bispecific Antibody**: Achieved a 26-day half-life and demonstrated effective inhibition of TSLP and IL-4R, with a goal of maximizing response in AD and asthma [14][15][17] Safety and Tolerability - **Injection Site Reactions (ISRs)**: Most common adverse event observed, generally mild and resolving without intervention [20][21] - **Overall Safety Profile**: Data from chronic toxicity studies and Phase 2a trials indicate a clean safety profile for lead compounds [73] Competitive Landscape and Market Opportunities - **JAK Inhibitor Market**: Aclaris aims to differentiate its products by focusing on more selective ITK inhibitors, which may have fewer immunosuppressive effects compared to traditional JAK inhibitors [35][63] - **Potential Indications**: Considering various inflammatory disorders, including alopecia and lichen planus, as potential targets for 2138 [45][46] Future Catalysts - **Upcoming Trials**: Phase 1b studies for AD and asthma are expected to provide significant data on efficacy and safety [24][28] - **IND Filing**: Planned for the next generation ITK compound towards the end of the year, with expectations to catch up to competitors [75] Conclusion Aclaris Therapeutics is positioned to make significant advancements in the biopharmaceutical space with its innovative therapies targeting atopic dermatitis and asthma. The company is focused on maximizing efficacy while maintaining a favorable safety profile, with several key trials and developments on the horizon.

Core Viewpoint - A securities fraud class action lawsuit has been filed against uniQure N.V. for allegedly misleading investors regarding the efficacy and regulatory approval timeline of its gene therapy AMT-130 for Huntington's disease [1][2] Company Overview - uniQure N.V. is a biotechnology company focused on developing gene therapies for rare diseases, particularly Huntington's disease [1] - The leading drug candidate, AMT-130, aims to slow the progression of Huntington's disease, a fatal genetic disorder with no current cure [1] Clinical Trials and FDA Interaction - uniQure completed patient enrollment for two ongoing Phase I/II clinical trials for AMT-130 in March 2022 [1] - The FDA had previously agreed that the Pivotal Study results could be compared to an external historical dataset (Enroll-HD) instead of using a placebo comparator [1] - The company claimed that the results indicated a significant reduction in neurodegeneration, leading to expectations of accelerated approval from the FDA [1] Stock Performance and Fundraising - Following the announcement of positive topline results on September 24, 2025, uniQure's stock price surged nearly 250%, from $13.66 to $47.50 per share [1] - The company subsequently raised approximately $345 million through a public offering of over 5.7 million shares, despite uncertainties regarding AMT-130's approval timeline [2] Disclosure of Material Information - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that the data from the Phase I/II studies would support a BLA submission, leading to a stock price drop of over 49% [2] - The lawsuit alleges that uniQure misrepresented the approval status of the Pivotal Study and downplayed the likelihood of delays in the BLA submission process [2]

Group 1 - The biotech sector is highlighted as a focus for investment opportunities, with a model portfolio featuring 12-20 high upside biotech stocks being offered [2] - The market remains resilient in 2026, despite cryptocurrencies losing nearly $2 trillion in value since their peak in October [2] - The volatility in precious metals is noted, particularly with silver experiencing significant daily price movements [2] Group 2 - The Biotech Forum provides live chat discussions on specific covered call trades, enhancing investor engagement and strategy sharing [1] - The group offers weekly market commentary and portfolio updates, which are essential for keeping investors informed [2]

Market Overview - Major stock indices experienced significant declines, with the Dow down 496.77 points (1.0%) at 49,624.63, the Nasdaq down 341.43 points (1.5%) at 22,725.04, and the S&P 500 down 68.04 points (1.0%) at 6,873.43 [1] Technology Sector - The sell-off was partly driven by a steep drop in Cisco Systems (CSCO), which fell by 10.7% despite reporting better-than-expected fiscal second-quarter results, as the company provided disappointing guidance for the current quarter [2] - The NYSE Arca Networking Index declined by 3.0% due to Cisco's performance [2] Transportation and Other Sectors - Transportation stocks saw a substantial decline, with the Dow Jones Transportation Average down by 5.1% [3] - Gold stocks weakened significantly, reflected by a 3.9% slump in the NYSE Arca Gold Bugs Index, attributed to a sharp decline in gold prices [3] - Financial, biotechnology, and oil service stocks also faced considerable weakness, while telecom and utilities stocks showed resilience against the downward trend [3] Economic Indicators - The Labor Department reported that initial jobless claims decreased to 227,000, down by 5,000 from the previous week's revised level of 232,000, which was less than economists' expectations of a drop to 220,000 [4][5] - Existing home sales pulled back more than expected in January, as reported by the National Association of Realtors [5] Inflation Outlook - Forecasts suggest that the core Consumer Price Index (CPI) could ease to around 2.5%, marking a near five-year low, which could influence market dynamics if inflation aligns with or falls below expectations [6] - A softer inflation print could maintain rate cuts and potentially restore upward momentum in risk assets [6] International Markets - In Asia-Pacific trading, South Korea's Kospi rose by 3.1%, while Hong Kong's Hang Seng Index fell by 0.9%, and Japan's Nikkei 225 Index closed marginally lower [6] - European markets showed mixed results, with the U.K.'s FTSE 100 Index down by 0.6%, while Germany's DAX Index rose by 0.1% and France's CAC 40 Index increased by 0.5% [7] Bond Market - Treasuries moved back to the upside, with the yield on the benchmark ten-year note down by 4.7 basis points at 4.125% [7]